Skip to content

Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q2Scopus Q2
Journal
JOURNAL OF CLINICAL HYPERTENSION22(10) · pp.1835 · 2020
Citation
Web of Science 14Scopus 14
FWCI (Scopus)
0
JCR IF
JCR 2019 2.719
ISSN
1524-6175

Authors

  1. Jin, XuanFirst authorDepartment of Cardiology, Dong-A University Hospital, Busan, Korea
  2. Kim, Moo HyunDepartment of Cardiology, Dong-A University Hospital, Busan, Korea
  3. Han, Ki HoonDivision of Cardiology, Department of Internal Medicine, Asan Medical Center, Seoul, Korea
  4. Hong, Soon JunDivision of Cardiology, Department of Cardiovascular Center, Korea University Anam Hospital, Seoul, Korea
  5. Ahn, Jeong-CheonDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea
  6. Sung, Jung-HoonDepartment of Cardiology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
  7. Cho, Jin-ManDivision of Cardiology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea
  8. Lee, Han CheolDivision of Cardiology, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea
  9. Choi, So-YeonDepartment of Cardiology, Ajou University School of Medicine, Suwon, Korea
  10. Lee, KyounghoonDivision of Cardiology, Gachon University Gil Medical Center, Incheon, Korea
  11. Kim, Woo-ShikDepartment of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea
  12. Rhee, Moo-YongCardiovascular Center, Dongguk University Ilsan Hospital, Goyang, Korea
  13. Kim, Ju HanDivision of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea
  14. Hong, Seung PyoDivision of Cardiology, Daegu Catholic University Medical Center, Daegu, Korea
  15. Yoo, Byung SuDivision of Cardiology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea
  16. Cho, Eun JooDivision of Cardiology, Department of Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
  17. Lee, Jae-HwanDepartment of Cardiology in Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea
  18. Kim, Pum-JoonDepartment of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
  19. Park, Chang-GyuDepartment of Internal Medicine, Korea University Guro Hospital, Seoul, Korea
  20. Hyon, Min SuDivision of Cardiology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea
  21. Shin, Jin HoDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
  22. LEE, Sang HyunDivision of Cardiology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea
  23. Sung, Ki ChulDivision of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Korea
  24. Hwang, JinyongDepartment of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, Korea
  25. Kwon, KihwanDepartment of Cardiology, Ewha Womans University College of Medicine, Seoul, Korea
  26. Chae, In-HoCardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea
  27. Seo, Jeong-SookDepartment of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
  28. Kim, HyungseopDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea
  29. Lee, HanaYuhan Research Institute, Yuhan Corporation, Yongin, Korea
  30. Cho, YoonhwaYuhan Research Institute, Yuhan Corporation, Yongin, Korea
Show all 31 authors

Abstract

Single risk factors, such as hypertension and dyslipidemia, can combine to exacerbate the development and severity of cardiovascular disease. Treatment goals may be more effectively achieved if multiple disease factors are targeted with combination treatment. We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg, telmisartan 80 mg + rosuvastatin 20 mg, and telmisartan/amlodipine 80/5 mg. The primary efficacy variables were changes from baseline in mean sitting systolic blood pressure (MSSBP) between telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan 80 mg + rosuvastatin 20 mg at 8 weeks, and the percent changes from baseline in low-density lipoprotein (LDL) cholesterol between telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan/amlodipine 80/5 mg at 8 weeks. The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up. There were no significant differences between the three groups in demographic characteristics and no significant difference among the three groups in terms of baseline characteristics for the validity evaluation variables. The mean overall treatment compliance in the three groups was, respectively, 98.42%, 96.68%, and 98.12%, indicating strong compliance for all patients. The Least-Square (LS) mean (SE) for changes in MSSBP in the two (telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan 80 mg + rosuvastatin 20 mg) groups were -19.3 (2.68) mm Hg and -6.69 (2.76) mm Hg. The difference between the two groups was significant (-12.60 (2.77) mm Hg, 95% CI -18.06 to -7.14,P < .0001). The LS Mean for the percent changes from baseline in LDL cholesterol in the two (telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan/amlodipine 80/5 mg) groups were -52.45 (3.23) % and 2.68 (3.15) %. The difference between the two groups was significant (-55.13 (3.20) %, 95% CI -61.45 to -48.81,P < .0001). There were no adverse events leading to discontinuation or death. Combined administration of telmisartan/amlodipine 80/5 mg and rosuvastatin 20 mg for the treatment of hypertensive patients with dyslipidemia significantly reduces blood pressure and improves lipid control. ClinicalTrials.gov identifier: NCT03067688.

Keywords

amlodipinedyslipidemiahypertensionrosuvastatintelmisartanFIXED-DOSE COMBINATIONSBLOOD-PRESSUREDOUBLE-BLINDMETAANALYSISAMLODIPINEPARTICIPANTSMULTICENTERMANAGEMENTSTATINS

Identifiers

Scopus EID
2-s2.0-85090984421
WoS UID
000569480400001